P-21 Dosage: What the Community Reports

P-21 has no clinically established human dose. It has never been studied in a human clinical trial, so the figures that circulate come from vendor listings and community discussion rather than pharmacokinetic data. The number referenced most often is roughly 500 mcg to 1 mg once daily, with a broader cited range of about 100 mcg to 2 mg per day, typically reconstituted from a lyophilized vial and dosed subcutaneously or intranasally.

That figure is real and widely circulated, but it is anecdotal and vendor-derived, not trial-validated. P-21's entire evidence base is preclinical rodent work — much of it from the lab that created the compound — and there is a notable mismatch between how those studies dosed it (oral and peripheral) and how community sources describe taking it (subcutaneous and intranasal).

Research-context information only. P-21 is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

P-21 (P021) is a synthetic adamantane-modified tetrapeptide (Ac-DGGLAG-NH2) derived from the active region of ciliary neurotrophic factor (CNTF). This guide reports the dose figures community sources reference, the route mismatch, and the all-preclinical evidence behind both — not a recommended protocol.

Quick Reference: Protocol

There is no standard protocol to publish here, because no human trial has defined one. The table below reports the figures that appear in vendor listings and community discussion. Every value is anecdotal and vendor-derived, not a recommendation.

These are microgram-to-low-milligram figures — far below the milligram ranges seen with some other nootropic peptides. The "dose in the morning" advice is itself community convention: a subset of users report overstimulation or sleep disruption with higher doses or later-day dosing. None of these numbers derives from human pharmacokinetic data, and no human safety data backs any cycle duration.

Routes of Administration

Community discussion and the preclinical literature diverge on route, with no human pharmacokinetic data to reconcile them.

• Subcutaneous injection: The route community sources most often describe. Because P-21 ships as a lyophilized vial, this involves reconstituting with bacteriostatic water like a standard injectable peptide. Injection-site reactions are the generic risk for any reconstituted subcutaneous peptide.
• Intranasal: Also mentioned in community sources. Users describe local irritation as a non-specific anecdotal complaint.
• Oral / peripheral (preclinical): The rodent studies demonstrated efficacy with oral and peripheral administration. Community human use skews subcutaneous and intranasal instead — a route mismatch worth flagging, since the demonstrated animal data does not map onto the route people report using.

Frequency is usually described as once daily, in the morning.

Ready to buy? The single research-grade, COA-checked P-21 source we track:

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Reconstitution Quick Reference

Because P-21 ships lyophilized, community use involves bacteriostatic-water reconstitution like a standard injectable peptide. The figures below illustrate how a 5 mg vial maps onto the community-reported dose range — they are not a validated protocol, since no human dose has been established.

Vendor storage guidance commonly calls for keeping the sealed vial cool and away from light; reconstituted product is typically refrigerated per vendor instructions. Purity depends entirely on the supplier's certificate of analysis (vendors commonly claim roughly 98-99% by HPLC). P-21 is labeled research use only, not for human consumption. Because no human dose has been validated, any concentration figure here is illustrative arithmetic, not a documented protocol.

Where These Numbers Come From

The dose figures above are not anchored to any human study, because none exists. There are no published human clinical trials of P-21 — no Phase 1, no human pharmacokinetics, no toxicology dossier, and no registered trials on ClinicalTrials.gov. The figures come from vendor product pages and community discussion, which is why this guide frames them as reported rather than recommended.

The compound's reputation rests instead on a coherent, mostly single-lab body of rodent work published roughly 2010-2019, developed in Khalid Iqbal's lab from an effort to pare the neurotrophic activity of Cerebrolysin down to a single defined molecule. The foundational paper introduced P21 (Ac-DGGLAG-NH2) and reported enhanced memory, neurogenesis, and synaptic plasticity in normal mice (Li 2010, PMID 20600002). Subsequent rodent studies reported reduced age-related cognitive decline in aged rats with chronic oral dosing (Bolognin 2014, PMID 24702821); disease-modifying effects in a 3xTg-AD Alzheimer's model, including reduced tau pathology and preserved synapses (Kazim 2014, PMID 25046994); reduced brain and CSF total tau in aged rats, with the compound shown to be blood-brain-barrier permeable (Khatoon 2015, PMID 26401692); and rescue of memory deficits in a Down syndrome model alongside increased BDNF and phospho-CREB and decreased GSK-3β (Kazim 2017, PMID 28368015).

Two points keep that record honest. First, the direction across studies is consistent — neurogenesis up, tau down, synaptic markers preserved, maze learning improved — and the literature is clean of retractions or integrity flags. That is a genuine strength relative to some other nootropic peptides whose foundational papers were retracted. Second, it is all rodent-model data, much of it single-lab, in disease and aging models, with zero human data and no cognitive-enhancement data in healthy people. "Disease-modifying in a mouse model" is not "works in people."

One mechanistic nuance is worth preserving: although P-21 is derived from a CNTF active region, the procognitive effect these papers describe is attributed largely to a BDNF-mediated cascade rather than classical CNTF receptor signaling. The "CNTF peptide" shorthand is accurate as to origin, but the mechanism the authors describe runs through BDNF and GSK-3β.

Stacking Protocols

Community sources sometimes describe pairing P-21 with other nootropic compounds, but there is no trial-validated stacking protocol and no human safety data for any combination. Because P-21 itself has never been characterized in humans, layering additional unapproved research chemicals compounds the uncertainty rather than resolving it. This guide does not report specific stack doses, as none rest on documented human evidence.

Side Effects & Safety

Human safety data for P-21 does not exist — there is no human toxicology or pharmacokinetic data of any kind. Rodent studies reported tolerability with chronic oral dosing and did not flag overt toxicity in the published readouts, but comprehensive toxicology has not been published, and rodent tolerability is not a human safety profile.

• Community-reported (anecdotal): Sleep disruption or overstimulation is the most consistently mentioned complaint, especially at higher doses or evening dosing — the basis for the common "dose in the morning" advice. Headache, irritability, or feeling "wired" are mentioned occasionally. Injection-site reactions (subcutaneous) and local irritation (intranasal) are the generic, non-specific risks for those routes.
• Theoretical (mechanistic): P-21 acts in models by upregulating neurotrophic and neurogenic signaling (BDNF, neurogenesis). Chronic potentiation of growth and proliferative signaling is the generic caution raised for any neurotrophic compound. Unlike some other nootropic peptides, there is no specific cancer-pathway literature tying P-21 to malignancy and no published study reporting such an effect, so this is generic mechanistic reasoning, not a P-21-specific finding.
• Reports are inconsistent: Some community sources describe noticeable effects, others describe little or nothing, and none of it is placebo-controlled. There is no validated human results timeline to separate signal from expectation.